Evidence map›Paper›PMID 39400233›Full record

ArticleRadiology. Imaging cancer2024

Mathematical 3D Liver Model for Surgical versus Ablative Therapy Treatment Planning for Colorectal Liver Metastases: Recommendations from the COLLISION and COLDFIRE Trial Expert Panels.

Bente A T van den Bemd, Robbert S Puijk, Han Keijzers, Petrousjka M van den Tol, Martijn R Meijerink, COLLISION Trial Group

2 registry-linked trialsAbstract read
In one paragraph

Article in Radiology. Imaging cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02082782 phase2completednot on this map

Colorectal Metastatic Liver Disease: Efficacy of Irreversible Electroporation (IRE) - a Phase II Clinical Trial (COLDFIRE-2 Study)

TypeinterventionalSponsorAmsterdam UMC, location VUmcRan2014 to 2020Enrolled51ConditionsColorectal Liver MetastasesArmsIrreversible electroporation (IRE)
NCT03088150 naunknown statusnot on this map

COLLISION Trial - Colorectal Liver Metastases: Surgery vs Thermal Ablation, a Phase III Single-blind Prospective Randomized Controlled Trial

TypeinterventionalSponsorAmsterdam UMC, location VUmcRan2017 to 2024Enrolled618ConditionsColoRectal Cancer, Liver Metastasis Colon Cancer, Liver Metastases, SurgeryArmsThermal ablation, Surgical resection
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Bente A T van den BemdFrom the Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands (B.A.T.v.d.B., R.S.P., M.R.M.); Cancer Center Amsterdam, Amsterdam, the Netherlands (B.A.T.v.d.B., R.S.P., M.R.M.); Department of Surgical Oncology, OLVG Hospital, Oost, Amsterdam, the Netherlands (B.A.T.v.d.B.); Department of Radiology and Nuclear Medicine, OLVG Hospital, Oost, Amsterdam, the Netherlands (R.S.P.), Department of Medical Physics and Radiation Protection, Haaglanden MC, The Hague, the Netherlands (H. Keijzers); and Department of Surgical Oncology, Medical Center Leeuwarden, Leeuwarden, the Netherlands (P.M.v.d.T.).ORCID 0000-0001-7203-2077
Robbert S PuijkFrom the Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands (B.A.T.v.d.B., R.S.P., M.R.M.); Cancer Center Amsterdam, Amsterdam, the Netherlands (B.A.T.v.d.B., R.S.P., M.R.M.); Department of Surgical Oncology, OLVG Hospital, Oost, Amsterdam, the Netherlands (B.A.T.v.d.B.); Department of Radiology and Nuclear Medicine, OLVG Hospital, Oost, Amsterdam, the Netherlands (R.S.P.), Department of Medical Physics and Radiation Protection, Haaglanden MC, The Hague, the Netherlands (H. Keijzers); and Department of Surgical Oncology, Medical Center Leeuwarden, Leeuwarden, the Netherlands (P.M.v.d.T.).ORCID 0000-0003-3293-4433
Han KeijzersFrom the Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands (B.A.T.v.d.B., R.S.P., M.R.M.); Cancer Center Amsterdam, Amsterdam, the Netherlands (B.A.T.v.d.B., R.S.P., M.R.M.); Department of Surgical Oncology, OLVG Hospital, Oost, Amsterdam, the Netherlands (B.A.T.v.d.B.); Department of Radiology and Nuclear Medicine, OLVG Hospital, Oost, Amsterdam, the Netherlands (R.S.P.), Department of Medical Physics and Radiation Protection, Haaglanden MC, The Hague, the Netherlands (H. Keijzers); and Department of Surgical Oncology, Medical Center Leeuwarden, Leeuwarden, the Netherlands (P.M.v.d.T.).
Petrousjka M van den TolFrom the Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands (B.A.T.v.d.B., R.S.P., M.R.M.); Cancer Center Amsterdam, Amsterdam, the Netherlands (B.A.T.v.d.B., R.S.P., M.R.M.); Department of Surgical Oncology, OLVG Hospital, Oost, Amsterdam, the Netherlands (B.A.T.v.d.B.); Department of Radiology and Nuclear Medicine, OLVG Hospital, Oost, Amsterdam, the Netherlands (R.S.P.), Department of Medical Physics and Radiation Protection, Haaglanden MC, The Hague, the Netherlands (H. Keijzers); and Department of Surgical Oncology, Medical Center Leeuwarden, Leeuwarden, the Netherlands (P.M.v.d.T.).ORCID 0000-0002-0206-8741
Martijn R MeijerinkFrom the Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands (B.A.T.v.d.B., R.S.P., M.R.M.); Cancer Center Amsterdam, Amsterdam, the Netherlands (B.A.T.v.d.B., R.S.P., M.R.M.); Department of Surgical Oncology, OLVG Hospital, Oost, Amsterdam, the Netherlands (B.A.T.v.d.B.); Department of Radiology and Nuclear Medicine, OLVG Hospital, Oost, Amsterdam, the Netherlands (R.S.P.), Department of Medical Physics and Radiation Protection, Haaglanden MC, The Hague, the Netherlands (H. Keijzers); and Department of Surgical Oncology, Medical Center Leeuwarden, Leeuwarden, the Netherlands (P.M.v.d.T.).
COLLISION Trial GroupFrom the Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands (B.A.T.v.d.B., R.S.P., M.R.M.); Cancer Center Amsterdam, Amsterdam, the Netherlands (B.A.T.v.d.B., R.S.P., M.R.M.); Department of Surgical Oncology, OLVG Hospital, Oost, Amsterdam, the Netherlands (B.A.T.v.d.B.); Department of Radiology and Nuclear Medicine, OLVG Hospital, Oost, Amsterdam, the Netherlands (R.S.P.), Department of Medical Physics and Radiation Protection, Haaglanden MC, The Hague, the Netherlands (H. Keijzers); and Department of Surgical Oncology, Medical Center Leeuwarden, Leeuwarden, the Netherlands (P.M.v.d.T.).

Funding

NCI NIH HHS NCT00102544NCI NIH HHS NCT02594202NCI NIH HHS NCT03354416
6 · The paper itself

Abstract

Purpose To further define anatomic criteria for resection and ablation using an expert panel-based three-dimensional liver model to objectively predict local treatment recommendations for colorectal liver metastases (CRLM). Materials and Methods This study analyzed data from participants with small CRLM (≤3 cm) considered suitable for resection, thermal ablation, or irreversible electroporation (IRE), according to a multidisciplinary expert panel, who were included in two prospective multicenter trials (COLLISION [NCT03088150] and COLDFIRE-2 [NCT02082782]) between August 2017 and June 2022. Ten randomly selected participants were used to standardize the model's Couinaud segments. CRLM coordinates were measured and plotted in the model as color-coded lesions according to the treatment recommendations. Statistical validation was achieved through leave-one-out cross-validation. Results A total of 611 CRLM in 202 participants (mean age, 63 [range, 29-87] years; 138 male and 64 female) were included. Superficially located CRLM were considered suitable for resection, whereas more deep-seated CRLM were preferably ablated, with the transition zone at a subsurface depth of 3 cm. Ninety-three percent (25 of 27) of perihilar CRLM treated with IRE were at least partially located within 1 cm from the portal triad. Use of the model correctly predicted the preferred treatment in 313 of 424 CRLM (73.8%). Conclusion The results suggest that CRLM can be defined as superficial (preferably resected) and deep-seated (preferably ablated) if the tumor center is within versus beyond 3 cm from the liver surface, respectively, and as perihilar if the tumor margins extend to within 1 cm from the portal triad.

Indexed as

Ablation TechniquesColorectal NeoplasmsLiver NeoplasmsAdultAgedAged, 80 and overClinical Trials, Phase II as TopicFemaleHepatectomyHumansImaging, Three-DimensionalLiverMaleMiddle AgedModels, TheoreticalMulticenter Studies as TopicAbdomen/GIAblation TechniquesCTLiverMetastasesMRIOncology

Identifiers

PMID39400233
PMCPMC11615634

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.